Couldn't agree more Groberts. The whole Medivet foray was a...

Couldn't agree more Groberts. The whole Medivet foray was a costly lesson. But I think the current management team have been reasonably adept in repositioning whilst admitting the errors/issues and focusing on growth in the core business.

Sales are growing nicely, and new revenue streams provide good potential to continue at or better than the current growth rate. I’m pleased with the comments of investing in sales team, systems and Sales monitoring tools. This bodes incredibly well for maximising output, without the need for ballooning management levels.

Given MLA is debt free and has roughly enough cash to cover at least another quarter at the current rate of cash burn (which should be much less now that Medivet has been disposed of). There is also the possibility that further funds may be returned from the medivet sale, although I’m not banking on anything, this would be an added plus. I think/hope that this is ground-zero and we’re onwards and upwards from here.

The final upbeat comment in the ‘outlook’ section update, summarises all the reasons I’m still holding and confident in the prospects of the company.

“Having finalised the divestment of its interest in MediVet, the Board and Management of MLA are confident the
Company will return to profitable and cash positive trading, giving it the financial flexibility to fast track its
strategy to expand sales, add supply and distribution agreements, consider geographic expansion and assess
accretive acquisitions.”

Dak, As Grobert mentioned, I for one will be contacting the company in advance so that I can plan around the AGM dates in Sydney this year. I look forward to meeting some fellow holders and quizzing management on any questions I may have later this year.


GLTA, DYOR, IMO etc…